While NCE may be a continued psychological overhang, a potential major catalyst, possibly more important than a favorable NCE ,is set to come any day now...
I am referring to the acceptance of AMRN's sNDA for Anchor by FDA. Many may overlook the event and assume this is just normal process. But you'd be missing something - a possible massive mitigation of risk for a pharma acquirer. With Anchor, it is highly unlikely outcomes trial will be needed to market to the larger indication. But, the FDA can confirm this for AMRN, either at sNDA acceptance (any time now) or FDA approval of the indication (later in the year). To be honest, I'm not 100% sure which one is most likely in this case and I am trying to confirm now.
Once confirmed, pharma companies would have what they need, a clear picture on when they can go to market for Anchor. Again, the assumption is no issues and no outcomes required but if you were going to fork up billions for AMRN, you would need to make sure- a heck of a lot more important than NCE.
Stay tuned, will get interesting fast.